ArticleJournal of oncology2022
SERPINE1 Overexpression Promotes Malignant Progression and Poor Prognosis of Gastric Cancer.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 109 citations in OpenAlex.
- Pharmacogenomic characterization of a uric acid metabolism-related signature associated with prognosis and drug sensitivity in gastric cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Identification and validation of an m1A-score model to predict outcomes and immunomodulation in lung squamous cell carcinoma by integrated analysis of single-cell and bulk RNA sequencing.Discover oncology · 2026Article
- High-Glucose Environment Promotes Radioresistance in Colorectal Cancer via SERPINE1-Enhanced DNA Repair and Anti-Apoptosis.International journal of medical sciences · 2026Article
- Article
- Ovatodiolide overcomes cisplatin resistance in head and neck cancer by disrupting a novel oncogenic signature and cancer-associated fibroblast activation.Journal of dental sciences · 2026Article
- The Association of EGFL7 Polymorphism and Expression with Cervical Cancer Susceptibility and Pathogenesis.International journal of general medicine · 2026Article
- Deciphering the oncogenic role of key genes in HNSC: insights from multi-omics and functional studies.Discover oncology · 2025Article
- Exploring the role of lipid metabolism genes in gastric cancer prognosis and tumor immune microenvironment.The Journal of international medical research · 2025Article
- Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis.Nature communications · 2025Article
- RNACOREX - RNA coregulatory network explorer and classifier.PLoS computational biology · 2025Article
- Mechanism of action ofOncology letters · 2025Article
- A novel machine learning-based predictive model for gastric cancer.Translational cancer research · 2025Article
- Hippo Signaling Dysregulation in Breast Cancer: Subtype-Independent Gene and miRNA Signatures.Biomedicines · 2025Article
- Uncovering the Tumorigenic Blueprint of PFOS and PFOA Through Multi-Organ Transcriptomic Analysis of Biomarkers, Mechanisms, and Therapeutic Targets.Current issues in molecular biology · 2025Article
- Dissecting cross-lineage tumourigenesis under p53 inactivation through single-cell multi-omics and spatial transcriptomics.Clinical and translational medicine · 2025Article
- Article
- Molecular Evidence for Altered Angiogenesis in Neuroinflammation-Associated Schizophrenia and Bipolar Disorder Implicate an Abnormal Midbrain Blood-Brain Barrier.Schizophrenia bulletin · 2025Article
- Comprehensive analysis of prognosis and drug sensitivity of programmed cell death pattern-related genes in gastric cancer patients.Scientific reports · 2025Article
- Identification and validation of extracellular matrix-related genes in the progression of gastric cancer with intestinal metaplasia.World journal of gastrointestinal oncology · 2025Article
- NFATC2/SERPINE1/JAK3/STAT3 signaling feedback loop in gastric cancer: immune evasion and anti-PD-1 resistance.Cell biology and toxicology · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The serine protease inhibitor clade E member 1 (SERPINE1) is a major inhibitor of tissue plasminogen activator and urokinase, and has been implicated in the development and progression of a variety of tumors. In this study, mRNA microarray and TCGA database were used to comprehensively analyze the upregulation of SERPINE1 in gastric cancer (GC) tissues compared with the normal stomach tissues. Kaplan-Meier results confirmed that patients with high SERPINE1 expression exhibited worse overall survival and disease-free survival. In addition, cell proliferation, cell scratches, transwell migration and invasion assay showed that SERPINE1 knockdown inhibited the proliferation, migration and invasion of GC ells. Western blot showed that the expression of VEGF and IL-6 was significantly upregulated after overexpression of SERPINE1. Meanwhile, SERPINE1 was positively correlated with the level of immune infiltration using the online analysis tools TISIDB and TIMER. And SERPINE1 expression increased with the increase of malignancy of GC which were detected by Immunohistochemistry. Finally, tumorigenesis experiments in nude mice further demonstrated that SERPINE1 could promote the occurrence and development of GC, while deletion of SERPINE1 inhibited the progression of GC. In summary, SERPINE1 was highly expressed in GC tissues, and SERPINE1 was helpful for differential diagnosis of pathological grade of gastric mucosal lesions. SERPINE1 might regulate the expression of VEGF and IL-6 through the VEGF signaling pathway and JAK-STAT3 inflammatory signaling pathway, thus ultimately affecting the invasion and migration of GC cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.